G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Angela Nebbioso,Angela Nebbioso,Vincenzo Carafa,Mariarosaria Conte,Francesco Paolo Tambaro,Francesco Paolo Tambaro,Ciro Abbondanza,Joost H.A. Martens,Joost H.A. Martens,Matthias Nees,Rosaria Benedetti,Isabella Pallavicini,Saverio Minucci,Guillermo Garcia-Manero,Francesco Iovino,Gabriella Lania,Concetta Ingenito,Valeria Belsito Petrizzi,Hendrik G. Stunnenberg,Lucia Altucci +19 more
TL;DR: A key role is identified for c-Myc in TRAIL deregulation and as a biomarker of the anticancer action of HDACi in AML, which could pave the way toward personalized therapies.
Journal ArticleDOI
Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours.
Masafumi Murai,Minoru Toyota,Ayumi Satoh,Hiromu Suzuki,Kimishige Akino,Hiroaki Mita,Yasushi Sasaki,Tadao Ishida,Lanlan Shen,Guillermo Garcia-Manero,Jean Pierre J. Issa,Yuji Hinoda,Takashi Tokino,Kohzoh Imai +13 more
TL;DR: Results suggest that aberrant DNA methylation of the 5′ CpG island and histone deacetylation play key roles in silencing BNIP3 expression in haematopoietic tumours.
Journal ArticleDOI
Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate
Yumin Hu,Weiqin Lu,Gang Chen,Hui Zhang,Yu Jia,Yue Wei,Hui Yang,Wan Zhang,Warren Fiskus,Kapil N. Bhalla,Michael J. Keating,Peng Huang,Guillermo Garcia-Manero +12 more
TL;DR: It is suggested that ROS plays an important role in action of vorinostat and that combination with a redox-modulating compound increases sensitivity to HDACIs and also overcomes vor inostat resistance.
Journal ArticleDOI
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
Farhad Ravandi,Jeffrey L. Jorgensen,Susan O'Brien,Elias Jabbour,Deborah A. Thomas,Gautam Borthakur,Rebecca Garris,Xuelin Huang,Guillermo Garcia-Manero,Jan A. Burger,Alessandra Ferrajoli,William G. Wierda,Tapan M. Kadia,Nitin Jain,Sa A. Wang,Sergei Konoplev,Partow Kebriaei,Richard E. Champlin,Deborah McCue,Zeev Estrov,Jorge E. Cortes,Hagop M. Kantarjian +21 more
TL;DR: Investigation of the prognostic value of minimal residual disease assessed by multi‐parameter flow cytometry among 340 adult patients with B‐cell acute lymphoblastic leukaemia treated between 2004 and 2014 indicated that MRD negative status at CR was an independent predictor of DFS and OS.
Journal ArticleDOI
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
Rami S. Komrokji,Guillermo Garcia-Manero,Lionel Ades,Thomas Prebet,David P. Steensma,Joseph G. Jurcic,Mikkael A. Sekeres,Jesus G. Berdeja,Michael R. Savona,Odile Beyne-Rauzy,Aspasia Stamatoullas,Amy E. DeZern,Jacques Delaunay,Gautam Borthakur,Robert M. Rifkin,Thomas E. Boyd,Abderrhamane Laadem,Bond Vo,Jennie Zhang,Marie Puccio-Pick,Kenneth M. Attie,Pierre Fenaux,Alan F. List +22 more
TL;DR: Sotatercept, a novel activin receptor type IIA fusion protein, was well tolerated and effective for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes in whom previous ESA treatment had failed.